allcancercure.com

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that it has submitted a clinical trial application (CTA) to initiate a phase 1 trial using the HuCAL-derived antibody MOR103 for the treatment of Rheumatoid Arthritis. MorphoSys plans to reveal the target molecule of its lead antibody program MOR103 and additional information on the design [...]

The Arthritis Foundation, the leading health organization addressing the needs of 46 million Americans living with arthritis, announced that Amgen and Wyeth Pharmaceuticals, co-marketers of Enbrel® (etanercept), will be the national presenting sponsor of the 2008 Arthritis Walk®.
“The Arthritis Foundation hosts hundreds of Arthritis Walk events nationwide to raise funds to prevent, control and cure [...]

Affecting more than 10 million Americans, Osteoarthritis of the knee (OA) is one of the five leading causes of disability among the elderly. While OA mainly affects most people over 45, it can occur at any age. A double-blind, placebo-controlled study published in the journal Nutrition Research reveals Pycnogenol, (pic-noj-en-all), an antioxidant plant extract from [...]

Total hip arthroplasty (THA), or hip replacement, is an effective treatment for osteoarthritis (OA), but most studies have only followed patients for up to one year. A new study published in the December issue of Arthritis Care & Research examined patients after an average of eight years following hip replacement and found a long-term positive [...]

Two fibro-cartilaginous crescents, the menisci serve as cushions against joint cartilage degradation where the knee connects with the shin and thigh bones. Loss of meniscal function is recognized as a strong risk factor for knee osteoarthritis (OA). In the United States, about 6 percent of the over 30 through middle-age population and between 11 and [...]

Osteoarthritis (OA) of the hip is a growing problem that will continue to increase as the population ages. Previous studies have reported on risk factors for developing OA, but few have examined the factors that might predict its prognosis. A new study published in the December issue of Arthritis Care & Research examined patients with [...]

Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced positive one-year interim results in the evaluation of Chondrogen, a preparation of adult stem cells formulated for direct injection into the knee. The one year data showed improvement in joint condition that correlated with a clinically and statistically significant improvement in pain in patients with osteoarthritis (OA) who received Chondrogen [...]

MedImmune, Inc. announced that dosing of patients has begun in the first Phase 1 clinical trial of CAM- 3001, a fully human monoclonal antibody (MAb) targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). The study is designed to evaluate the safety and tolerability of single doses of CAM-3001 in patients with [...]

Actemra is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody seeking approval to treat rheumatoid arthritis
Roche announced the submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for Actemra (tocilizumab) to reduce the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA).
“The filing for [...]

GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced the initiation of the Phase III programme with ofatumumab to treat rheumatoid arthritis (RA). The programme will commence with two studies (OFA110635/GEN410 and OFA110634/GEN411), which will be conducted outside the US, in two distinct patient populations. One study will be in patients who have had an inadequate [...]